Compare PSEC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | COLL |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | PSEC | COLL |
|---|---|---|
| Price | $2.69 | $36.63 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 4.1M | 387.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 20.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.55 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $2.45 | $23.23 |
| 52 Week High | $4.36 | $50.79 |
| Indicator | PSEC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 20.03 |
| Support Level | $2.55 | $34.30 |
| Resistance Level | $2.71 | $39.85 |
| Average True Range (ATR) | 0.09 | 1.58 |
| MACD | -0.02 | -0.78 |
| Stochastic Oscillator | 8.75 | 3.15 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.